Paul Mouncey
paulmouncey.bsky.social
Paul Mouncey
@paulmouncey.bsky.social
Researcher in critical care. Co-Director at Intensive Care National Audit & Research Centre.
Reposted by Paul Mouncey
16,500 patients randomised to #UKROXTrial presented just now at #CCR25 and simultaneously published in @jama.com

No difference in 90d mortality between target SpO2 88-92 with reduced exposure to supplemental O2 vs usual care

jamanetwork.com/journals/jam...
Conservative Oxygen Therapy With Mechanical Ventilation
This randomized clinical trial assesses whether reducing supplemental oxygen to a peripheral oxygen saturation target of 90% would reduce mortality among critically ill adults receiving mechanical ven...
jamanetwork.com
June 12, 2025 at 8:48 AM
Reposted by Paul Mouncey
Conservative oxygen therapy with a target SpO2 of 90% did not reduce 90-day all-cause mortality compared to usual oxygen therapy in mechanically ventilated adult patients.

#CCR25 @criticalcarereviews.com

ja.ma/4mZgVl6
June 13, 2025 at 4:52 PM
Reposted by Paul Mouncey
Editorial: The UK-ROX trial demonstrates that targeting lower oxygen saturation in critically ill patients is safe but does not improve outcomes.

#CCR25 @criticalcarereviews.com

ja.ma/3FxWhYu
June 13, 2025 at 4:52 PM
Reposted by Paul Mouncey
🚨UK-ROX TRIAL Results at #CCR25🚨

📍 ~100 🇬🇧 ICUs
👥 ~16,500 pts
🎯 Conservative vs usual oxygen therapy in invasively ventilated adults
🩺 Outcome: Mortality day 90

🤔 Will less oxygen save lives?

📺 Free livestream — but it's better in person!
🔗 criticalcarereviews.com/ccr25
May 31, 2025 at 3:58 PM
Reposted by Paul Mouncey
The third trial result for #CCR25 in Titanic Belfast in June is the UK-Rox Trial

Evaluating the clinical & cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in ICU

Register via the QR code or on the CCR website
criticalcarereviews.com/meetings/ccr25
January 10, 2025 at 6:21 PM